Just months af­ter SPAC re­verse merg­er, Point Bio­phar­ma ups the ante at In­di­anapo­lis man­u­fac­tur­ing site

Point Bio­phar­ma trot­ted out to near-uni­corn sta­tus in March as part of a re­verse merg­er with a SPAC backed by RA Cap­i­tal’s Pe­ter Kolchin­sky to back its ra­di­oli­gand play. Now, the up­start crew is plant­i­ng its man­u­fac­tur­ing flag with a ma­jor plant in the works.

Point Bio­phar­ma is fin­ish­ing ren­o­va­tions to an 80,000-square-foot cen­ter that will be­come one of the largest ra­di­oli­gand fa­cil­i­ties in the world up­on com­ple­tion, the com­pa­ny said in a re­lease. The fa­cil­i­ty will hold an NRC Ma­te­ri­als Li­cense, which au­tho­rizes the han­dling of nu­clear ma­te­r­i­al and al­lows Point to work with ra­dioiso­topes on site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER